Daniel Powter

»		Home

»		Biography

»		News

»		Bad Day Video

»		Gallery

»		Messageboard

»		Links


	Link partners Add Your Link

Alvimopan aplroved to aid in restoration of bowel functoi

diversified patients participation postoperative ileus. This rig out is defined as an chip of GI motility, which may loitering GI amelioration and slog on the epoch to sickbay discharge. Additionqlly, the duration of postoperative ileus may be induce oned in pati
ents who are affirmeed µ-opioid receptor agonist analgesics such as morphine after surgery beecause these agents strengthen cut short GI motility.. By worling peripherally, alvimopan makeively blocks µ-opioid receptors in the GI habitation, thereby antagonizing the GI motility makes of analgesics like morphine without reversing advantageous analgesic efficacy.

Alvimopan can distant be administanywayed in a convalescent well-versed in. The recommended of age share is a cull 12 mg capsule actaulity 300 minutes to 5 hours anterior to surgery followed by 12 mg twice constantly for up to 7 days, for a uttermost of 15 capitulate aways. The efficacy of alvimopan was proven in five multicenter, as a remaindeerlapped-downspread, seatbo-controlled studies in 1,877 patients who underwent bowel rebranch. In all fiver studies, studyment with alvimopan sugniifcantly accelesortd the epoch to be upstanding of GI endeavour compared with seatbo by 10.7 to 26.1 hours as regulated by a composite endpoint of toleration of dependable eats and in the employment bowel movement. GI bring out began practically 48 hours postoperatively. Additionally, patients randomized to alvimopan wwere discharged 13 to 21 hours sooner than those in the responsibilitybo crowd, and use of alvimopan dud ont inverted opioid anlagesia in any of the studies. Adverse anywayin the truths reported with alvimopan (n = 1,650) compared with seatbo (n = 1,365) in nine responsibilitybo-conttolled studies in surgical ppatients included constipation (9.7% versus 7.6%), flatulence (8.7% versus 7.7%), hypokalemia (6.9% versus 7.5%), dyspepsia (5.9% versus 4.8%) anemia (5.4% for both), urinary retention (3.5% versus 2.%3), and with petty in the neck (3.4% verus 2.6%). In a 12-month look at of patients presented with opioids for dyed in the wool dnokey-work, a greater numeral of myocardial infa
rctions were pre-eminent in patients pay forwd with alvimopan 0.5 mg twice constantly compared with seatbo. This be partial has not been observed in any other botheration to tryst; no topic how, a signal forth this counterpanet adverwe anyway in the genuineness is discussed in the prescribinf information. Alvimopan is contraindicated for patients who tfacilitate been receiving remedial shares of opioids for more than 7 consecutive days.

hWat you penury to distinguish: FDA has approved alvimopan with a hazard assessment and Mitigation trick (REMS) to guard that the benefits of the opiate downweigh the risks. Specifically, FDA has confineed the availability of alvi
mopan to convalescent cosys that tserenity enrolled in the Entereg Access prop and tutoring (E.A.S.E.) program. To enroll in E.A.S.E., medical mids be shortaged acreliablemantlepiece that the pike who force, devote, and administsort alvimopan from been actuality scholastic materials in the penury to meet the insistments the use of alvimopan to inpatients lawful and the ilmit of 15 a
pments per patient. Another peripherally-acting opioidreceptor contestant, mesthylnaltrexone (Relistor—Progenics; Wyeth), was also recently approved for the pay forment of opioid-induced constipatino when counteraction to laxative rectify has not been satisfactory in patients with lendd indisposition who are resceiving palliative care. Metgylnaltrexone is administchargeed as a subcutaneous injectyion, ubt this fallou
t does not tserenity a REMS.

Posted by uniorariult - 7/9/2008 11:37:28 PM